Back to top
more

Penumbra (PEN)

(Real Time Quote from BATS)

$188.55 USD

188.55
49,215

-1.32 (-0.70%)

Updated Jul 22, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Inspire (INSP) Gets FDA Nod for Expanded Indication of AHI

by Zacks Equity Research

The FDA approves Inspire's (INSP) application to expand the indication to include patients with AHI up to 100 events per hour.

Illumina (ILMN) Sequencing Arm Grows, Margin Woes Linger

by Zacks Equity Research

Illumina's (ILMN) total sequencing activity on connected high- and mid-throughput instruments are growing strongly.

Charles River (CRL) to Aid INADcure in Plasmid DNA Manufacture

by Zacks Equity Research

Charles River (CRL) collaborates with INADcure Foundation on plasmid DNA manufacturing for developing treatments for INAD patients.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.

UnitedHealth Group (UNH) Hikes Quarterly Dividend by 14%

by Zacks Equity Research

UnitedHealth Group's (UNH) recent dividend hike highlights a solid financial position and efforts to sustain its sound capital deployment history.

Bruker (BRKR) Launches timsTOF Ultra Mass Spec and VistaScan

by Zacks Equity Research

Bruker (BRKR) introduces the timsTOF Ultra mass spectrometer and VistaScan software for enhanced dia-PASEF 4D-Proteomics at the 71st ASMS meeting.

Zacks.com featured highlights include Penumbra, Lamb Weston Holdings, Transportadora de Gas del Sur and Vipshop

by Zacks Equity Research

Penumbra, Lamb Weston Holdings, Transportadora de Gas del Sur and Vipshop are part of the Zacks Screen of the Week article.

Syneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes

by Zacks Equity Research

Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.

LabCorp (LH) Provides Update on Planned Spinoff of Fortrea

by Zacks Equity Research

After separation from LabCorp (LH), Fortrea is set to operate as a global contract research organization that offers comprehensive drug and medical device development services.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher's (TMO) continued strength across its end markets and the the execution of the growth strategy.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Sail Through Choppy Market

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and Vipshop Holdings (VIPS) are poised to gain.

Penumbra (PEN) Launches New Technology for Blood Clot Removal

by Zacks Equity Research

Penumbra (PEN) launches Lightning Bolt 7, a new technology that can remove blood clots faster and more efficiently with modulated aspiration.

Quest Diagnostics' (DGX) Contract Wins Aid Amid Volume Woes

by Zacks Equity Research

Quest Diagnostics (DGX) succeeds on contract wins in its reference and professional lab services offerings.

Here's Why You Should Invest in IDEXX (IDXX) Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX) on the strength of the Companion Animal Group business.

Bruker's (BRKR) Latest Workflows to Aid Applied Markets

by Zacks Equity Research

Bruker (BRKR) introduces Novel EVOQ DART-TQ+ for chromatography-free mass spectrometry for applied markets.

Here's Why You Should Invest in Edward Lifesciences (EW) Now

by Zacks Equity Research

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCB

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and its strategies to accelerate growth.

LabCorp (LH) Expands Precision Oncology With Biopsy Test

by Zacks Equity Research

The addition of Labcorp Plasma Focus marks a pivotal step in the expansion of LabCorp's (LH) suite of precision oncology tests.

Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23

by Zacks Equity Research

At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Medtronic (MDT) on the robust performances of the Neurosurgery and Cardiovascular portfolios.

Here's Why You Should Retain Integra (IART) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Revised)

by Zacks Equity Research

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.